Brokerages Set Certara, Inc. (NASDAQ:CERT) PT at $15.67

Certara, Inc. (NASDAQ:CERT - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine ratings firms that are covering the stock, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $15.71.

CERT has been the subject of a number of analyst reports. JMP Securities restated a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. Morgan Stanley assumed coverage on shares of Certara in a research note on Thursday. They issued an "equal weight" rating and a $16.00 target price for the company. Barclays raised shares of Certara from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $11.00 to $14.00 in a research report on Thursday, May 8th. Robert W. Baird lifted their price objective on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. Finally, KeyCorp upped their target price on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, April 16th.

Certara Stock Down 1.6%

Shares of CERT traded down $0.18 during mid-day trading on Wednesday, hitting $11.31. 200,899 shares of the company's stock were exchanged, compared to its average volume of 1,446,103. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.78 and a quick ratio of 2.78. Certara has a 52 week low of $8.64 and a 52 week high of $16.93. The company has a market cap of $1.83 billion, a PE ratio of -565.10 and a beta of 1.43. The company has a 50-day simple moving average of $11.77 and a 200 day simple moving average of $11.85.

Certara (NASDAQ:CERT - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.04. Certara had a negative net margin of 0.67% and a positive return on equity of 5.05%. The business had revenue of $106.00 million during the quarter, compared to the consensus estimate of $104.44 million. During the same quarter last year, the firm earned $0.10 earnings per share. The firm's revenue for the quarter was up 9.7% compared to the same quarter last year. On average, research analysts forecast that Certara will post 0.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Jane Street Group LLC boosted its holdings in shares of Certara by 17.1% during the first quarter. Jane Street Group LLC now owns 277,054 shares of the company's stock worth $2,743,000 after acquiring an additional 40,463 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Certara by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company's stock worth $2,965,000 after purchasing an additional 35,954 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Certara by 65.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company's stock valued at $2,267,000 after purchasing an additional 90,724 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in Certara in the 1st quarter valued at $297,000. Finally, Select Equity Group L.P. grew its holdings in Certara by 534.5% in the 1st quarter. Select Equity Group L.P. now owns 1,094,495 shares of the company's stock valued at $10,836,000 after buying an additional 922,007 shares in the last quarter. 73.96% of the stock is owned by institutional investors.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.